GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GENELUX Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.45+0.03 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $110.15M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.27 (−57.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
GENELUX Corp grew revenue 0.0% to $8.00K over fiscal 2025. Free cash flow was -$28.68M.
Revenue
$8.00K
0.0% vs. a year earlier
Operating income
-$36.42M
TTM Q2 2026
Free cash flow
-$28.68M
TTM Q2 2026
EPS, diluted
-$0.86
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $110.15M
- P/E ratio
- –
- Price to sales
- 13768.82
- Price to book
- 6.84
- Dividend yield
- –
- Free cash flow yield
- -26.04%
Fundamentals
- Revenue
- $8.00K
- Net income
- -$35.60M
- EPS, diluted
- -$0.86
- Free cash flow
- -$28.68M
- Book value per share
- $0.36
- Diluted shares
- 45M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$36.42M
Net income
-$35.60M
EPS, diluted
-$0.86
Free cash flow
-$28.68M
Reported periodTrailing twelve months